摘要
目的观察拉米夫定和α-2b干扰素联合治疗HBeAg阳性慢性乙型肝炎的早期疗效以及安全性。方法71例HBeAg阳性慢性乙型肝炎分为联合治疗组(23例)、干扰素组(27例)和拉米夫定组(21例)。联合治疗组口服拉米夫定(100mg/d)24周,第9周加用干扰素α-2b(5MU/d肌内注射,2周后改隔日肌内注射)至24周;干扰素组单用α-2b干扰素(5MU/d肌内注射,2周后改隔日肌内注射)24周;拉米夫定组单用拉米夫定(100mg/d)24周。结果治疗24周时,联合治疗组和干扰素组HBeAg血清转换率分别为43.37%和33.33%明显高于拉米夫定组(9.52%),P<0.05;联合治疗组、干扰素组和拉米夫定组HB-VDNA阴转率分别为56.52%、28.57%和48.14%,无显著性差异(P>0.05)。血清ALT复常率,联合治疗组(60.89%)和拉米夫定组(51.85%)显著高于干扰素组(19.04%),P<0.05。结论拉米夫定和α-2b干扰素联合治疗慢性乙型肝炎早期应答优于单用拉米夫定或干扰素。
Objective To observe the early efficacy and safety of combined sequential administration of lamivudine and interferon al- fa-2b in patients with hepatitis Be antigen （HBeAg） -positive chronic hepatitis B. Methods 71 patients were divided into combined therapy growp （23 eases） ,interferon group （27 cases） and lamivudine group （21 cases）, patients in the first group were given sequential combination treatment with of lamivudine monotherapy for nine weeks followed by lamivudine plus interferon alfa - 2b for 15 weeks while patients in the interferon group and Lamivudine group received interferon alfa -2b monotherapy and lamivudine respectively. Results At 24weeks, 43.37% of the patients who received sequential combination treatment and 33.33% of those who received interferon alfa - 2b monotherapy had H BeAg seroconversion,which is higher than those who received lamivudine monotherapy（9.52% , P 〈 0. 05 ）. 56.52% of the patients who received sequential combination treatment , 28.57% of who received interferon alfa - 2b and 48.14% of those who received interferon alfa - 2b monotherapy had HBV - DNA levels below 1000 copies/mL （ P 〉 0.05 ）. The normolization rates of ALT in combining group , interferon group and Lamivudine group were 60.87% , 51.85% and 19.04% respectively（ P 〈 0.05）. Conclusion Sequential combination treatment is able to improve early response rates in patients with HBeAg-posifive chronic hepatitis B.
出处
《医学研究杂志》
2008年第6期91-93,共3页
Journal of Medical Research
关键词
拉米夫定
干扰素
慢性乙型肝炎
Lamivudine
Interferon α-2b
Chronic hepatitis B
